These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7728772)

  • 1. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
    Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
    Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
    Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
    Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
    Chong AS; Aleksijevic A; Scuderi P; Hersh EM; Grimes WJ
    Cancer Immunol Immunother; 1989; 29(4):270-8. PubMed ID: 2502310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
    Furbert-Harris PM; Evans CH
    Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased interleukin-15 from activated cord versus adult peripheral blood mononuclear cells and the effect of interleukin-15 in upregulating antitumor immune activity and cytokine production in cord blood.
    Qian JX; Lee SM; Suen Y; Knoppel E; van de Ven C; Cairo MS
    Blood; 1997 Oct; 90(8):3106-17. PubMed ID: 9376592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
    Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
    Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
    Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
    Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.
    Cesano A; Visonneau S; Clark SC; Santoli D
    J Immunol; 1993 Sep; 151(6):2943-57. PubMed ID: 8104216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products.
    Gibson FM; Malkovska V; Myint AA; Meager A; Gordon-Smith EC
    Exp Hematol; 1991 Aug; 19(7):659-63. PubMed ID: 1909968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
    Puri RK; Leland P
    Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
    Ozdemir O; Ravindranath Y; Savaşan S
    J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells.
    Cesano A; Visonneau S; Deaglio S; Malavasi F; Santoli D
    J Immunol; 1998 Feb; 160(3):1106-15. PubMed ID: 9570523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.